CHARTER Resources Home News Stories CHARTER Investigators Present at CROI 2012

CHARTER Investigators Present at CROI 2012

CHARTER investigators presented the following abstracts at the 19th Conference on Retroviruses and Opportunistic Infections that took place in Seattle, Washington on March 5-8, 2012.

  1. Blackstone K, Moore DJ, Woods SP, Morgan EE, Franklin DR, Ellis RJ, Letendre SL, Grant I, Heaton RK, and the CHARTER Group. (2012). How “asymptomatic” is HIV-associated asymptomatic neurocognitive impairment?
  2. Burdo T, Weiffenbach A, Woods S, Letendre L, Ellis R, Williams K. (2012). Elevated sCD163 in NP impaired HIV+ individuals despite virally suppressive ART.
  3. Choi JY, Heaton R, Grant I, Marcotte T, Ellis R, Letendre R, Marra C, Clifford D, Richman D, Smith D. (2012). Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat.
  4. Croteau D, Best BM, Umlauf A, Clifford DB, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Simpson DM, Grant I, Letendre S. (2012). Older age is associated with higher antiretroviral concentrations in cerebrospinal fluid in HIV-infected individuals.
  5. Ellis R, Gelman B, Letendre S, Clifford D, Marra C, McArthur J, McCutchan J,Simpson D, Grant I, and the CHARTER Group. (2012). Elevated soluble CD14 levels in cerebrospinal fluid in aging HIV-­infected individuals with sensory neuropathy despite virally suppressive antiretroviral therapy.
  6. Haughey N, Mielke M, Bandaru V, Sacktor N, Grant I, Letendre S, Fox H, Chang L, Wozna V, Pardo C, McArthur J. (2012). A lipidomic analysis of CSF from HIV-infected subjects identifies metabolites that predict change in cognitive performance.
  7. Heaton R, Deutsch R, Franklin D, Woods S, Collier A, Clifford D, Gelman B, McArthur J, Simpson D, Grant I. (2012). Prevalence and predictors of neurocognitive decline over 18 to 42 months: A CHARTER longitudinal study.
  8. Heaton R, Franklin D, Woods S, Marra C, Clifford D, Gelman B, McArthur J, Morgello S, McCutchan A, and Grant I. (2012). Asymptomatic mild HIV-associated neurocognitive disorders increase risks for future symptomatic cognitive decline: A CHARTER longitudinal study.
  9. Letendre S, Bharti A, Perez Valero I, Landay A, Hanson, Franklin D, Woods S, Heaton R, Grant I, Lurain N. (2012). Higher cytomegalovirus (CMV) antibody concentrations are associated with older age, lower nadir CD4+ cell counts, and worse global neurocognitive (NC) functioning in people with HIV disease.
  10. Letendre S, Marcotte T, Deutsch R, Franklin D, Rosario D, Alexander T, Haughey N, Pardo C, Fox H, Grant I. (2012). A concise panel of biomarkers diagnoses and predicts neurocognitive (NC) status in HIV-Infected individuals.
  11. Letendre SL, Vaida F, Ellis R, Clifford D, Gelman B, Marra C, McArthur J, McCutchan A,  Simpson D, Grant I, and the CHARTER Group. (2012). Longitudinal Correlates of HIV RNA Levels in 2,207 CSF Specimens.
  12. McCutchan JA, Marquie-Beck J, FitzSimons C, Letendre S, Ellis RJ, Heaton R, Wolfson T, Marra C, Ances B, Grant I, for the CHARTER Group. (2012). Role of central obesity, diabetes, and metabolic variables in HIV-associated neurocognitive disorder.
  13. Perez-Valero I, Heaton R, Letendre S, McCutchan JA, Clifford D, McArthur J, Morgello S,Gelman B, Collier A, Grant I, and the CHARTER Group. (2012). Validation of the EACS guidelines 2011 algorithm for detecting HAND in the CHARTER Cohort.

Click Here for Posters to view for select abstracts above.  A Poster is available for viewing if there is a link in the left hand column next to the abstract title.


Sponsored by NIH/NIMH/NINDS HHSN271201000036C & HHSN271201000030C

Copyright ©2010 CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH | University of California, San Diego | contact the webmaster